TNFRSF8 and Hodgkins lymphoma: In their clinical trials, Wang and colleagues evaluated the response following anti-CD30 CAR T-cell infusion in 18 patients with r/r HL and reported an overall response rate (ORR) of 39%17, while Ramos et al. reported nine patients who with a 33% ORR and the efficacy may due to the higher disease burden which seven out of nine patients resistance to several cycling brentuximab treatment manifested18.